阿霉素搭载蛙皮素应用于乳腺癌化疗的动物实验研究  

Animal Experimental Study on the Application of Doxorubicin in the Treatment of Breast Cancer with Chemotherapy

作　　者：李建强[1] 王会东[2] 王昌亮[2] 李宗兰[1] 

机构地区：[1]潍坊医学院外科学教研室,山东潍坊261053 [2]潍坊市人民医院乳腺外科

出　　处：《潍坊医学院学报》2016年第6期463-466,共4页Acta Academiae Medicinae Weifang

摘　　要：目的实验室合成蛙皮素活性肽、阿霉素、固体脂质纳米粒构成的高效复合物(Bn-DOX/SLNs),通过动物实验评估Bn-DOX/SLNs抗人乳腺癌细胞的作用。方法实验室合成Bn-DOX/SLNs,测定并比较BnDOX/SLNs与对照组粒子的理化特性包括粒子大小、表面点位量测、药物负载量、诱导药物能力、体外药物的释放效率,并评测在动物模型中抗人乳腺癌细胞的作用。结果 Bn-DOX/SLNs能明显降低人乳腺癌细胞MCF-7/MDR对阿霉素的耐药性,并且能在小鼠体内明显提高阿霉素抗人乳腺癌细胞的活性。结论 Bn-DOX/SLNs能明显降低阿霉素的耐药性,可用于临床乳腺癌患者的化疗。Objective Modified bombesin DOX-loaded solid lipid nanoparticles（ Bn-DOX/SLNs） were synthesized. The effect of Bn-DOX / SLNs on human breast cancer cells was evaluated by animal experiments. Methods BnDOX / SLNs were constructed. The physicochemical properties of the Bn-DOX / SLNs were investigated by particle size and zeta potential measurement,drug loading and drug-entrapment efficiency,and in vitro drug release behavior. In vitro cytotoxicity against MCF-7 / MDR cells were investigated,and the role of anti human breast cancer cells in animal models was evaluated. Results Bn-DOX / SLNs showed an excellent in vitro cytotoxicity and in vivo anti-tumor effect both in MCF-7 / MDR breast cancer cells and breast cancer animal model. Conclusion The results indicate that Bn-DOX / SLNs obviously reverse the resistance of doxorubicin,suggesting that chemotherapy using Bn-modified nanocarriers may benefit human breast MDR cancer therapy.

关 键 词：蛙皮素 阿霉素 乳腺肿瘤 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]